Navigation Links
China Pharma Holdings, Inc. to Initiate Clinical Trials For New Antibiotic Combination

China's SFDA Approves Entry into Clinical Trials on Schedule

HAIKOU CITY, China, Oct. 29 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, announced today that its novel antibiotic combination formula has been granted approval by China's State Food and Drug Administration (SFDA) to enter clinical trials.

The Company will initiate clinical trials in November 2008 to evaluate this drug, a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor, for the treatment of infections. The development timeline is consistent with the company's predictions.

China Pharma's CEO and president, Ms Zhilin Li, commented, "We are pleased that the SFDA has approved our new antibiotic formula to enter clinical trials within our anticipated timeframe. We look forward to initiating and completing these clinical trials over the next two years and hope to confirm previous results that showed significant efficacy in clearing antibiotic resistant bacterial strains. Antibiotic resistance is a growing global problem that requires the development of more advanced treatment to effectively combat resistant strains. Pending successful clinical development, this therapy could capture market share in China from Cephalosporin antibiotics used to address various infections, including hospital-acquired and respiratory infections, bacterial meningitis, and pneumonia."

Microbial antibiotic resistance has emerged as a major public health problem in China and throughout the world. Many Cephalosporins marketed in China, including third generation Cephalosporins, have encountered bacterial resistance. Surveillance in China up to 2005 shows that 20% to 70% of certain target pathogen strains may be resistant to one or more third generation Cephalosporins.(*) Despite this drug resistance, China's market for Cephalosporin antibiotics was approximately CNY 25.2 billion (USD$3.68 billion) in 2006 and is predicted to exceed CNY 38.3 billion (USD$5.6 billion) in 2008.(**)

(*)Source: Eur.J.Clin.Microbiol.Infect.Dis. 2008 Aug; 27(8) 697-708. Xiao

YH, Wang J, Li Y. -- Bacterial Resistance Surveillance in China, a

report from the MOH National Antimicrobial Resistance Investigation Net


(**)Source: SFDA information center

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a biopharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost- effective, high margin business model is driven by market demand and supported by 8 scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across more than 29 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit .

Safe Harbor Statement

Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

China Pharma Holdings, Inc.

Diana Huang

Tel: +86-898-6681-1730


The Ruth Group

Sara Ephraim

Tel: +1-646-536-7002


SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
(Date:11/28/2015)... ... , ... Pixel Film Studios is back again with ProPanel: Pulse . ... endless. Users have full control over angle of view, speed method, start point, end ... to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, ...
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, ... in light of the recent terrorist attacks in Paris, other cities are taking extra ... from reaching U.S. soil. Especially around special events that may be high-profile in nature, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/25/2015)... Nov. 25, 2015 ... of the "Global Brain Monitoring Devices ... --> ) has announced ... Monitoring Devices Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology: